IMNN insider filings
Imunon, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-10. Screen IMNN transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 23 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing by 1 insider — 2,525 shares, $3,950 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
- Largest priced transaction: sale of 2,525 shares @ $1.56 ($3,950) by Eylward Susan, filed 2026-09-01.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Eylward Susan — General Counsel and Corp Sec | 1 | — | 1 leg · 2,525 sh · $3,950 | 1 |
| Faller Douglas Vincent — Chief Medical Officer | 6 | — | — | 7 |
| Lindborg Stacy — President and CEO, Director | 6 | — | — | 6 |
| Tardugno Michael H — Executive Chairman of Board, Director | 6 | — | — | 6 |
| Braun Donald P — Director | 1 | — | — | 1 |
| Dentzer James E — Director | 1 | — | — | 1 |
| Fritz Frederick J. — Director | 1 | — | — | 1 |
| Pellizzari Christine A — Director | 1 | — | — | 1 |
Recent insider filings — Imunon, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-10 | 4 | Dentzer James E — Director | Grant/award (A): 13,166 @ $0.84 | EDGAR |
| 2026-11-10 | 4 | Braun Donald P — Director | Grant/award (A): 11,746 @ $0.84 | EDGAR |
| 2026-11-10 | 4 | Fritz Frederick J. — Director | Grant/award (A): 13.17 @ $0.84 | EDGAR |
| 2026-11-10 | 4 | Pellizzari Christine A — Director | Grant/award (A): 13,166 @ $0.84 | EDGAR |
| 2026-11-10 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 3,804 @ $0.84 | EDGAR |
| 2026-11-10 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 1,596 @ $0.84 | EDGAR |
| 2026-11-10 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 9,969 @ $0.84 | EDGAR |
| 2026-10-27 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 2,603 @ $1.24 | EDGAR |
| 2026-10-27 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 6,821 @ $1.24 | EDGAR |
| 2026-10-27 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 26,741 @ $1.24 · Grant/award (A): 1,092 @ $1.24 | EDGAR |
| 2026-10-13 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 7,800 @ $1.08 | EDGAR |
| 2026-10-13 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 2,977 @ $1.08 | EDGAR |
| 2026-10-13 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 1,249 @ $1.08 | EDGAR |
| 2026-09-28 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 4,390 @ $1.41 | EDGAR |
| 2026-09-28 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 6,697 @ $1.41 | EDGAR |
| 2026-09-28 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 7,169 @ $1.41 | EDGAR |
| 2026-09-15 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 4,211 @ $1.47 | EDGAR |
| 2026-09-15 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 5,504 @ $1.47 | EDGAR |
| 2026-09-15 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 5,824 @ $1.47 | EDGAR |
| 2026-09-01 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 3,626 @ $1.60 | EDGAR |
| 2026-09-01 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 6,822 @ $1.60 | EDGAR |
| 2026-09-01 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 7,371 @ $1.60 | EDGAR |
| 2026-09-01 | 4 | Eylward Susan — General Counsel and Corp Sec | Grant/award (A): 2,525 @ $1.60 · Sale (S): 2,525 @ $1.56 | EDGAR |
| 2026-08-17 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 7,147 @ $1.65 | EDGAR |
| 2026-08-17 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 3,516 @ $1.65 | EDGAR |
| 2026-08-17 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 6,615 @ $1.65 | EDGAR |
| 2026-08-17 | 4 | Eylward Susan — General Counsel and Corp Sec | Grant/award (A): 2,449 @ $1.65 · Sale (S): 2,449 @ $1.63 | EDGAR |
| 2026-08-04 | 4 | Braun Donald P — Director | Grant/award (A): 6,180 @ $1.59 | EDGAR |
| 2026-08-04 | 4 | Fritz Frederick J. — Director | Grant/award (A): 6,934 @ $1.59 | EDGAR |
| 2026-08-04 | 4 | Dentzer James E — Director | Grant/award (A): 6,934 @ $1.59 | EDGAR |
| 2026-08-04 | 4 | Pellizzari Christine A — Director | Grant/award (A): 6,934 @ $1.59 | EDGAR |
| 2026-08-04 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 5,010 @ $1.59 | EDGAR |
| 2026-08-04 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 3,649 @ $1.59 | EDGAR |
| 2026-08-04 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 6,358 @ $1.59 | EDGAR |
| 2026-08-04 | 4 | Eylward Susan — General Counsel and Corp Sec | Grant/award (A): 2,541 @ $1.59 · Sale (S): 2,541 @ $1.57 | EDGAR |
| 2026-07-21 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 3,082 @ $1.83 | EDGAR |
| 2026-07-21 | 4 | Eylward Susan — General Counsel and Corp Sec | Grant/award (A): 2,150 @ $1.83 · Sale (S): 2,150 @ $1.78 | EDGAR |
| 2026-07-21 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 4,907 @ $1.83 | EDGAR |
| 2026-07-21 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 4,603 @ $1.83 | EDGAR |
| 2026-07-07 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 1,308 @ $1.91 | EDGAR |
| 2026-07-07 | 4 | Eylward Susan — General Counsel and Corp Sec | Grant/award (A): 920 @ $1.91 · Sale (S): 920 @ $1.88 | EDGAR |
| 2026-07-07 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 2,534 @ $1.91 | EDGAR |
| 2026-07-07 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 4,410 @ $1.91 | EDGAR |
| 2026-06-29 | 4 | Faller Douglas Vincent — Chief Medical Officer | Grant/award (A): 21,896 @ $1.72 | EDGAR |
| 2026-06-29 | 4 | Eylward Susan — General Counsel and Corp Sec | Grant/award (A): 14,696 @ $1.72 · Sale (S): 11,800 @ $1.75 | EDGAR |
| 2026-06-29 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 67,150 @ $1.72 | EDGAR |
| 2026-06-29 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 42,519 @ $1.72 | EDGAR |
| 2026-06-23 | 4 | Lindborg Stacy — President and CEO, Director | Grant/award (A): 1,803 @ $1.82 | EDGAR |
| 2026-06-23 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 4,629 @ $1.82 | EDGAR |
| 2026-06-09 | 4 | Tardugno Michael H — Executive Chairman of Board, Director | Grant/award (A): 4,089 @ $2.06 | EDGAR |
Recent 8-K events — Imunon, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-27 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-21 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Registration filings — Imunon, Inc.
Securities Act registration lifecycles tracked for this issuer (live-forward since 2026-08-01), threaded by SEC file number.
- SEC file 333-299647 (S-1) — latest: Amendment (S-1/A), filed 2026-10-28
GET https://api.filingpulse.io/v1/insider-trades?ticker=IMNN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs